Suppr超能文献

遗传性皮肤疾病的新型分子疗法。

Novel molecular therapies for heritable skin disorders.

机构信息

Departments of Dermatology and Cutaneous Biology, and Biochemistry and Molecular Biology, Jefferson Medical College, and Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

出版信息

J Invest Dermatol. 2012 Mar;132(3 Pt 2):820-8. doi: 10.1038/jid.2011.389. Epub 2011 Dec 8.

Abstract

Tremendous progress has been made in the past two decades in molecular genetics of heritable skin diseases, and pathogenic mutations have been identified in as many as 500 distinct human genes. This progress has resulted in improved diagnosis with prognostic implications, has refined genetic counseling, and has formed the basis for prenatal and presymptomatic testing and preimplantation genetic diagnosis. However, there has been relatively little progress in developing effective and specific treatments for these often devastating diseases. However, very recently, a number of novel molecular strategies, including gene therapy, cell-based approaches, and protein replacement therapy, have been explored for the treatment of these conditions. This overview will focus on the prototypic heritable blistering disorders, epidermolysis bullosa, and related keratinopathies, in which significant progress has been made recently toward treatment, and it will illustrate how some of the translational research therapies have already entered the clinical arena.

摘要

在过去的二十年中,遗传性皮肤疾病的分子遗传学取得了巨大的进展,多达 500 个不同的人类基因已被确定为致病突变。这一进展改善了具有预后意义的诊断,完善了遗传咨询,并为产前、症状前检测和植入前遗传诊断奠定了基础。然而,在开发这些经常是毁灭性疾病的有效和特异性治疗方法方面,进展相对较少。然而,最近,许多新的分子策略,包括基因治疗、基于细胞的方法和蛋白质替代疗法,已经被探索用于这些疾病的治疗。本综述将重点介绍最近在治疗方面取得显著进展的典型遗传性水疱性疾病——大疱性表皮松解症和相关的角蛋白病,并说明一些转化研究疗法如何已经进入临床领域。

相似文献

1
Novel molecular therapies for heritable skin disorders.
J Invest Dermatol. 2012 Mar;132(3 Pt 2):820-8. doi: 10.1038/jid.2011.389. Epub 2011 Dec 8.
2
Cell-based therapies for epidermolysis bullosa - from bench to bedside.
J Dtsch Dermatol Ges. 2012 Nov;10(11):803-7. doi: 10.1111/j.1610-0387.2012.08035.x.
3
Molecular therapeutics for heritable skin diseases.
J Invest Dermatol. 2012 Nov 15;132(E1):E29-34. doi: 10.1038/skinbio.2012.9.
5
Progress in molecular genetics of heritable skin diseases: the paradigms of epidermolysis bullosa and pseudoxanthoma elasticum.
J Investig Dermatol Symp Proc. 2002 Dec;7(1):6-16. doi: 10.1046/j.1523-1747.2002.19637.x.
6
Revertant mosaicism in skin: natural gene therapy.
Trends Mol Med. 2011 Mar;17(3):140-8. doi: 10.1016/j.molmed.2010.11.003. Epub 2010 Dec 29.
7
Molecular therapies for heritable blistering diseases.
Trends Mol Med. 2009 Jul;15(7):285-92. doi: 10.1016/j.molmed.2009.05.004. Epub 2009 Jul 4.
8
Stem Cell Therapy for Epidermolysis Bullosa-Does It Work?
J Invest Dermatol. 2016 Nov;136(11):2119-2121. doi: 10.1016/j.jid.2016.07.004.
9
DNA-based prenatal diagnosis of heritable skin diseases.
Arch Dermatol. 1993 Nov;129(11):1455-9.
10
Keratin gene mutations in disorders of human skin and its appendages.
Arch Biochem Biophys. 2011 Apr 15;508(2):123-37. doi: 10.1016/j.abb.2010.12.019. Epub 2010 Dec 19.

引用本文的文献

1
Challenges in Treating Genodermatoses: New Therapies at the Horizon.
Front Pharmacol. 2022 Jan 5;12:746664. doi: 10.3389/fphar.2021.746664. eCollection 2021.
2
Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair.
Mol Ther Nucleic Acids. 2018 Sep 7;12:554-567. doi: 10.1016/j.omtn.2018.06.008. Epub 2018 Jun 26.
5
Identification of translational dermatology research priorities in the U.K.: results of an electronic Delphi exercise.
Br J Dermatol. 2015 Nov;173(5):1191-1198. doi: 10.1111/bjd.14022. Epub 2015 Oct 14.
6
From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.
Mol Ther. 2015 Jun;23(6):987-992. doi: 10.1038/mt.2015.47. Epub 2015 Mar 24.
7
A living band-aid for epidermolysis bullosa.
Blood Transfus. 2015 Jan;13(1):1-2. doi: 10.2450/2014.0289-14.
8
Bone marrow stromal cells as immunomodulators. A primer for dermatologists.
J Dermatol Sci. 2015 Jan;77(1):11-20. doi: 10.1016/j.jdermsci.2014.10.004. Epub 2014 Oct 31.
9
In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation.
J Control Release. 2014 Dec 28;196:355-62. doi: 10.1016/j.jconrel.2014.10.022. Epub 2014 Oct 30.
10
Modulating the stem cell niche for tissue regeneration.
Nat Biotechnol. 2014 Aug;32(8):795-803. doi: 10.1038/nbt.2978.

本文引用的文献

1
Zinc-finger Nucleases: The Next Generation Emerges.
Mol Ther. 2008 Jul;16(7):1200-1207. doi: 10.1038/mt.2008.114. Epub 2016 Dec 8.
2
Cell-based therapy for RDEB: how does it work?
J Invest Dermatol. 2011 Aug;131(8):1597-9. doi: 10.1038/jid.2011.125.
3
Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex.
J Invest Dermatol. 2011 Oct;131(10):2079-86. doi: 10.1038/jid.2011.169. Epub 2011 Jun 30.
5
Immunogenicity of induced pluripotent stem cells.
Nature. 2011 May 13;474(7350):212-5. doi: 10.1038/nature10135.
6
Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells.
Proc Natl Acad Sci U S A. 2011 May 24;108(21):8797-802. doi: 10.1073/pnas.1100332108. Epub 2011 May 9.
8
Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy.
Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6537-42. doi: 10.1073/pnas.1103388108. Epub 2011 Apr 4.
9
PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia.
Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6609-14. doi: 10.1073/pnas.1016753108. Epub 2011 Apr 4.
10
The phenotypic and molecular genetic features of pachyonychia congenita.
J Invest Dermatol. 2011 May;131(5):1015-7. doi: 10.1038/jid.2011.59. Epub 2011 Mar 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验